Complications and Mortality Rate of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy: Italian Peritoneal Surface Malignancies Oncoteam Results Analysis
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Nichiforkin, A.; Gushchin, V.; King, M.C.; Baron, E.; Nieroda, C.; Sittig, M.; Sardi, A. Surgical and oncological outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a nonacademic center: 25-year experience. J. Surg. Oncol. 2021, 123, 1030–1044. [Google Scholar] [CrossRef] [PubMed]
- Leigh, N.L.; Solomon, D.; Feingold, D.; Magge, D.R.; Golas, B.J.; Sarpel, U.; Labow, D.M. Improved Survival with Experience: A 10-Year Learning Curve in Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery. Ann. Surg. Oncol. 2020, 27, 222–231. [Google Scholar] [CrossRef] [PubMed]
- Carboni, F.; Federici, O.; Zazza, S.; Corona, F.; Massimi, F.; Sperduti, I.; Valle, M. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal metastasis of non-primary origin. Langenbecks Arch. Surg. 2021, 406, 2817–2825. [Google Scholar] [CrossRef] [PubMed]
- Passot, G.; Vaudoyer, D.; Villeneuve, L.; Kepenekian, V.; Beaujard, A.-C.; Bakrin, N.; Cotte, E.; Gilly, F.-N.; Glehen, O. What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: A 25-year experience with 1.125 procedures. J. Surg. Oncol. 2016, 113, 796–803. [Google Scholar] [CrossRef] [PubMed]
- Mielko, J.; Rawicz-Pruszyński, K.; Sędłak, K.; Gęca, K.; Kwietniewska, M.; Polkowski, W.P. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies: Learning Curve Based on Surgical and Oncological Outcomes. Cancers 2020, 23, 2387. [Google Scholar] [CrossRef]
- Kyang, L.S.; Alzahrani, N.A.; Valle, S.J.; Rahman, M.K.; Arrowaili, A.; Liauw, W.; Morris, D.L. Long-term survival outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy: Single-institutional experience with 1225 cases. J. Surg. Oncol. 2019, 120, 794–802. [Google Scholar] [CrossRef]
- Chua, T.C.; Yan, T.D.; Saxena, A.; Morris, D.L. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: A systematic review of morbidity and mortality. Ann. Surg. 2009, 249, 900–907. [Google Scholar] [CrossRef]
- Kusamura, S.; Gonzalez-Moreno, S.; Nizrri, E.; Baratti, D.; Guadagni, S.; Guaglio, M.; Battaglia, L.; Deraco, M. Learning curve, training program and monitorization of surgical performance of peritoneal surface malignancies centers. Surg. Oncol. Clin. N. Am. 2018, 27, 507–517. [Google Scholar] [CrossRef] [PubMed]
- Noiret, B.; Clement, G.; Lenne, X.; Bruandet, A.; Glehen, O.; Voron, T.; Piessen, G.; Eveno, C. Centralization and Oncologic Training Reduce Postoperative Morbidity and Failure-to-rescue Rates After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies: Study on a 10-year National French Practice. Ann. Surg. 2020, 272, 847–854. [Google Scholar] [CrossRef] [PubMed]
- Houlzé-Laroye, C.; Glehen, O.; Sgarbura, O.; Gayat, E.; Sourrouille, I.; Tuech, J.J.; Delhorme, J.-B.; Dumont, F.; Ceribelli, C.; Amroun, K.; et al. Half of Postoperative Deaths After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Could be Preventable: A French Root Cause Analysis on 5562 Patients. Ann. Surg. 2021, 274, 797–804. [Google Scholar] [CrossRef]
- Levine, E.A.; Stewart, J.H., 4th; Shen, P.; Russell, G.B.; Loggie, B.L.; Votanopoulos, K.I. Intraperitoneal chemotherapy for peritoneal surface malignancy: Experience with 1000 patients. J. Am. Coll. Surg. 2014, 218, 573–585. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Foster, J.M.; Sleightholm, R.; Patel, A.; Shostrom, V.; Hall, B.; Neilsen, B.; Bartlett, D.; Smith, L. Morbidity and Mortality Rates Following Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy Compared with Other High-Risk Surgical Oncology Procedures. JAMA Netw. Open 2019, 2, e186847. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kubi, B.; Gunn, J.; Fackche, N.; Cloyd, J.M.; Abdel-Misih, S.; Grotz, T.; Leiting, J.; Fournir, K.; Lee, A.J.; Dineen, S.; et al. Predictors of Non-home Discharge after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. J. Surg. Res. 2020, 255, 475–485. [Google Scholar] [CrossRef]
- Überrück, L.; Nadiradze, G.; Yurttas, C.; Königsrainer, A.; Königsrainer, I.; Horvath, P. In-Hospital Mortality and Complication Rates According to Health Insurance Data in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies in Germany. Ann. Surg. Oncol. 2021, 28, 3823–3830. [Google Scholar] [CrossRef]
- Piso, P.; Nedelcut, S.D.; Rau, B.; Königsrainer, A.; Glockzin, G.; Ströhlein, M.A.; Hörbelt, R.; Pelz, J. Morbidity and Mortality Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Data from the DGAV StuDoQ Registry with 2149 Consecutive Patients. Ann. Surg. Oncol. 2019, 26, 148–154. [Google Scholar] [CrossRef]
- Beal, E.W.; Ahmed, A.; Grotz, T.; Leiting, J.; Fournir, K.F.; Lee, A.J.; Dineen, S.; Dessureault, S.; Baumgartner, J.M.; Veerapong, J.; et al. Trends in the indications for short-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Am. J. Surg. 2020, 219, 478–483. [Google Scholar] [CrossRef]
- Jafari, M.D.; Halabi, W.J.; Stamos, M.J.; Nguyen, V.Q.; Carmichael, J.C.; Mills, S.D.; Pigazzi, A. Surgical outcomes of hyperthermic intraperitoneal chemotherapy: Analysis of the american college of surgeons national surgical quality improvement program. JAMA Surg. 2014, 149, 170–175. [Google Scholar] [CrossRef] [Green Version]
- Gani, F.; Conca-Cheng, A.M.; Nettles, B.; Ahuja, N.; Johnston, F.M. Trends in Outcomes after Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. J. Surg. Res. 2019, 234, 240–248. [Google Scholar] [CrossRef] [PubMed]
- Sugarbaker, P.H. Peritonectomy procedures. Surg. Oncol. Clin. N. Am. 2003, 12, 703–727. [Google Scholar] [CrossRef] [PubMed]
- Gonzalez-Moreno, S.; Ortega-Pérez, G.; Alonso-Casado, O.; Galipienzo-García, J.; Linero-Noguera, M.J.; Salvatierra-Díaz, D. Techniques and Safety Issues for Intraperitoneal Chemotherapy. Surg. Oncol. Clin. N. Am. 2018, 27, 495–506. [Google Scholar] [CrossRef]
- National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0. 2017. Available online: https://www.meddra.org/ (accessed on 1 December 2021).
- Tan, J.W.S.; Tan, G.H.C.; Ng, W.Y.; Ong, C.J.; Chia, C.S.; Soo, K.C.; Teo, M.C.C. High-grade complication is associated with poor overall survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Int. J. Clin. Oncol. 2020, 25, 984–994. [Google Scholar] [CrossRef] [PubMed]
- Choudry, M.H.A.; Shuai, Y.; Jones, H.L.; Pai, R.K.; Pingpank, J.F.; Ahrendt, S.S.; Holtzman, M.P.; Zeh, H.J.; Bartlett, D.L. Postoperative Complications Independently Predict Cancer-Related Survival in Peritoneal Malignancies. Ann. Surg. Oncol. 2018, 25, 3950–3959. [Google Scholar] [CrossRef] [PubMed]
- Lee, T.C.; Wima, K.; Morris, M.C.; Winer, L.K.; Sussman, J.J.; Ahmad, S.A.; Patel, S.H. Incidence and Long-term Outcomes of Patients Requiring Early Reoperation After HIPEC. J. Surg. Res. 2019, 244, 395–401. [Google Scholar] [CrossRef] [PubMed]
- Wiseman, J.T.; Abdel-Misih, S.; Beal, E.W.; Zaidi, M.Y.; Staley, C.A.; Grotz, T.; Leiting, J.; Fournier, K.; Lee, A.J.; Dineen, S.; et al. A multi-institutional analysis of Textbook Outcomes among patients undergoing cytoreductive surgery for peritoneal surface malignancies. Surg. Oncol. 2021, 37, 101492. [Google Scholar] [CrossRef]
- Alyami, M.; Kim, B.J.; Villeneuve, L.; Vaudoyer, D.; Képénékian, V.; Bakrin, N.; Gilly, F.-N.; Cotte, E.; Glehen, O.; Passot, G. Ninety-day post-operative morbidity and mortality using the National Cancer Institute’s common terminology criteria for adverse events better describe post-operative outcome after cytoreduction surgery and hyperthermic intraperitoneal chemotherapy. Int. J. Hypert. 2018, 34, 532–537. [Google Scholar] [CrossRef] [PubMed]
- Tabrizian, P.; Shrager, B.; Jibara, G.; Yang, M.J.; Romanoff, A.; Hiotis, S.; Sarpel, U.; Labow, D.M. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: Outcomes from a single tertiary institution. J. Gastrointest. Surg. 2014, 8, 1024–1031. [Google Scholar] [CrossRef]
- Desantis, M.; Bernard, J.L.; Casanova, V.; Cegarra-Escolano, M.; Benizri, E.; Rahili, A.M.; Benchimol, D.; Bereder, J.M. Morbidity, mortality, and oncological outcomes of 401 consecutive cytoreductive procedures with hyperthermic intraperitoneal chemotherapy (HIPEC). Langenbecks Arch. Surg. 2015, 400, 37–48. [Google Scholar] [CrossRef]
- Blaj, S.; Nedelcut, S.; Mayr, M.; Leebmann, H.; Leucuta, D.; Glockzin, G.; Piso, P. Re-operations for early postoperative complications after CRS and HIPEC: Indication, timing, procedure, and outcome. Langenbecks Arch. Surg. 2019, 404, 541–546. [Google Scholar] [CrossRef] [PubMed]
- Narasimhan, V.; Das, A.; Warrier, S.; Lynch, C.; McCormick, J.; Tie, J.; Micheal, M.; Ramsay, R.; Heriot, A. Evaluation of cytoreductive surgery and HIPEC for peritoneal surface malignancies: Analysis of 384 consecutive cases. Langenbecks Arch. Surg. 2019, 404, 527–539. [Google Scholar] [CrossRef]
- Carboni, F.; Federici, O.; Zazza, S.; Sperduti, I.; Valle, M. Feasibility of diaphragmatic interventions in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: A 20-year experience. Eur. J. Surg. Oncol. 2021, 47, 143–148. [Google Scholar] [CrossRef] [PubMed]
- Hentzen, J.E.K.R.; Constansia, R.D.N.; Been, L.B.; Hoogwater, F.J.H.; van Ginkel, R.J.; van Dam, G.M.; Hemmer, P.H.J.; Kruijff, S. Diagnostic Laparoscopy as a Selection Tool for Patients with Colorectal Peritoneal Metastases to Prevent a Non-therapeutic Laparotomy During Cytoreductive Surgery. Ann. Surg. Oncol. 2020, 27, 1084–1093. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Carboni, F.; Federici, O.; Giofrè, M.; Valle, M. An 18-year experience in diagnostic laparoscopy of peritoneal carcinomatosis: Results from 744 patients. J. Gastrointest. Surg. 2020, 24, 2096–2103. [Google Scholar] [CrossRef]
- von Breitenbuch, P.; Boerner, T.; Jeiter, T.; Piso, P.; Schlitt, H.J. Laparoscopy as a useful selection tool for patients with prior surgery and peritoneal metastases suitable for multimodality treatment strategies. Surg. Endosc. 2018, 32, 2288–2294. [Google Scholar] [CrossRef] [PubMed]
- Dranichnikov, P.; Graf, W.; Cashin, P.H. Readmissions after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy-a national population-based study. World J. Surg. Oncol. 2020, 6, 67. [Google Scholar] [CrossRef] [PubMed]
- Lee, T.C.; Wima, K.; Sussman, J.J.; Ahmad, S.A.; Cloyd, J.M.; Ahmed, A.; Fournier, K.; Lee, A.J. Readmissions After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A US HIPEC Collaborative Study. J. Gastrointest. Surg. 2020, 24, 165–176. [Google Scholar] [CrossRef] [PubMed]
- Paredes, A.Z.; Abdel-Misih, S.; Schmidt, C.; Dillhoff, M.E.; Pawlik, T.M.; Cloyd, J.M. Predictors of Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. J. Surg. Res. 2019, 234, 103–109. [Google Scholar] [CrossRef]
- Kelly, K.J.; Cajas, L.; MìBaumgartner, J.M.; Lowy, A.M. Factors Associated with 60-Day Readmission Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. Ann. Surg. Oncol. 2018, 25, 91–97. [Google Scholar] [CrossRef] [PubMed]
- Martin, A.S.; Abbott, D.E.; Hanseman, D.; Sussman, J.E.; Kenkel, A.; Greiwe, P.; Saeed, N.; Ahmad, S.H.; Sussman, J.J.; Ahmad, S.A. Factors Associated with Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis. Ann. Surg. Oncol. 2016, 23, 1941–1947. [Google Scholar] [CrossRef] [PubMed]
- Rieser, C.J.; Hall, L.B.; Kang, E.; Zureikat, A.H.; Holtzman, M.P.; Pingpank, J.F.; Bartlett, D.L.; Choudry, M.H.A. Predischarge Prediction of Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Derivation and Validation of a Risk Prediction Score. Ann. Surg. Oncol. 2021, 28, 5287–5296. [Google Scholar] [CrossRef] [PubMed]
- Baratti, D.; Kusamura, S.; Mingrone, E.; Balestra, M.R.; Laterza, B.; Deraco, M. Identification of a subgroup of patients at highest risk for complications after surgical cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann. Surg. 2012, 256, 334–341. [Google Scholar] [CrossRef] [PubMed]
- Burguete, D.; Mokdad, A.A.; Augustine, M.M.; Minter, R.; Mansour, J.C.; Choti, M.A.; Polanco, P.M. Non-home Discharge and Prolonged Length of Stay After Cytoreductive Surgery and HIPEC. J. Surg. Res. 2019, 233, 360–367. [Google Scholar] [CrossRef]
- Bartlett, E.K.; Meise, C.; Roses, R.E.; Fraker, D.L.; Kelz, R.R.; Karakousis, G.C. Morbidity and mortality of cytoreduction with intraperitoneal chemotherapy: Outcomes from the ACS NSQIP database. Ann. Surg. Oncol. 2014, 21, 1494–1500. [Google Scholar] [CrossRef] [PubMed]
- Leiting, J.L.; Cloyd, J.M.; Ahmed, A.; Fournier, K.; Lee, A.J.; Dessureault, S.; Felder, S.; Veerapong, J.; Baumgartner, J.M.; Clarke, C.; et al. Comparison of open and closed hyperthermic intraperitoneal chemotherapy: Results from the United States hyperthermic intraperitoneal chemotherapy collaborative. World J. Gastrointest. Oncol. 2020, 12, 756–767. [Google Scholar] [CrossRef] [PubMed]
- Helderman, R.F.C.P.A.; Löke, D.R.; Kok, H.P.; Oei, A.L.; Tanis, P.J.; Franken, N.A.P.K.; Crezee, J. Variation in Clinical Application of Hyperthermic Intraperitoneal Chemotherapy: A Review. Cancers 2019, 11, 78. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Marano, L.; Marrelli, D.; Sammartino, P.; Biacchi, D.; Graziosi, L.; Marino, E.; Coccolini, F.; Fugazzola, P.; Valle, M.; Federici, O.; et al. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer with Synchronous Peritoneal Metastases: Multicenter Study of ‘Italian Peritoneal Surface Malignancies Oncoteam-S.I.C.O.’. Ann. Surg. Oncol. 2021, 28, 9060–9070. [Google Scholar] [CrossRef] [PubMed]
- Yarema, R.; Mielko, J.; Fetsych, T.; Ohorchak, M.; Skorzewska, M.; Rawicz-Pruszyński, K.; Mashukov, A.; Maksimovsky, V.; Jastrzębski, T.; Polkowski, W.; et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) in combined treatment of locally advanced and intraperitonealy disseminated gastric cancer: A retrospective cooperative Central-Eastern European study. Cancer Med. 2019, 8, 2877–2885. [Google Scholar] [CrossRef] [Green Version]
- Konstantinidis, I.T.; Chouliaras, K.; Levine, E.A.; Lee, B.; Votanopoulos, K.I. Frailty Correlates with Postoperative Mortality and Major Morbidity After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. Ann. Surg. Oncol. 2017, 22, 3825–3830. [Google Scholar] [CrossRef]
- Keyes, A.M.; Kelly, M.E.; McInerney, N.; Khan, M.F.; Bolger, J.C.; McCormack, E.; Grundy, J.; McCormack, O.; MacHale, J.; Conneely, J.; et al. Short-term outcomes in older patients with peritoneal malignancy treated with cytoreductive surgery and HIPEC: Experience with 245 patients from a national centre. Eur. J. Surg. Oncol. 2021, 47, 2358–2362. [Google Scholar] [CrossRef] [PubMed]
- Gagnière, J.; Veziant, J.; Pereira, B.; Pezet, D.; Le Roy, B.; Slim, K. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for the Elderly: Is It Reasonable? A Meta-Analysis. Ann. Surg. Oncol. 2018, 25, 709–719. [Google Scholar] [CrossRef]
- Chambers, L.M.; Chalif, J.; Yao, M.; Chichura, A.; Morton, M.; Gruner, M.; Costales, A.B.; Horowitz, M.; Chau, D.B.; Vargas, R.; et al. Modified frailty index predicts postoperative complications in women with gynecologic cancer undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Gynecol. Oncol. 2021, 162, 368–374. [Google Scholar] [CrossRef]
- Dreznik, Y.; Hoffman, A.; Hamburger, T.; Ben-Yaacov, A.; Dux, Y.; Jacoby, H.; Berger, Y.; Nissan, A.; Gutman, M. Hospital readmission rates and risk factors for readmission following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal surface malignancies. Surgeon 2018, 16, 278–282. [Google Scholar] [CrossRef] [PubMed]
- Moon, E.W.; Wong, J.S.M.; See, A.H.M.; Ong, W.S.; Tan, C.A.; Ong, C.J.; Chia, C.S.; Soo, K.C.; Teo, M.C.C.; Tan, G.H.C. Predicting Early and Late Readmissions Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Ann. Surg. Oncol. 2021, 28, 6613–6624. [Google Scholar] [CrossRef] [PubMed]
- Esteve-Pérez, N.; Ferrer-Robles, A.; Gómez-Romero, G.; Fabián-Gonzalez, D.; Verd-Rodriguez, M.; Mora-Fernandez, L.C.; Segura-Sampedro, J.J.; Tejada-Gavela, S.; Morales-Soriano, R. Goal-directed therapy in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: A prospective observational study. Clin. Transl. Oncol. 2019, 21, 451–458. [Google Scholar] [CrossRef] [PubMed]
- Shamavonian, R.; McLachlan, R.; Fisher, O.M.; Valle, S.J.; Alzahrani, N.A.; Liauw, W.; Morris, D.L. The effect of intraoperative fluid administration on outcomes of patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J. Gastrointest. Oncol. 2019, 10, 235–243. [Google Scholar] [CrossRef] [PubMed]
- Hendrix, R.J.; Damle, A.; Williams, C.; Harris, A.; Spanakis, S.; Lambert, D.H.; Lambert, L.A. Restrictive Intraoperative Fluid Therapy is Associated with Decreased Morbidity and Length of Stay Following Hyperthermic Intraperitoneal Chemoperfusion. Ann. Surg. Oncol. 2019, 26, 490–496. [Google Scholar] [CrossRef]
- Fichmann, D.; Roth, L.; Raptis, D.A.; Kajdi, M.E.; Gertsch, P.; Vonlanthen, R.; de Rougemont, O.; Moral, J.; Beck-Schimmer, B.; Lehmann, K. Standard Operating Procedures for Anesthesia Management in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Improve Patient Outcomes: A Patient Cohort Analysis. Ann. Surg. Oncol. 2019, 26, 3652–3662. [Google Scholar] [CrossRef]
- Kubi, B.; Nudotor, R.; Fackche, N.; Nizam, W.; Cloyd, J.M.; Grotz, T.E.; Fournier, K.F.; Dineen, S.P.; Powers, B.D.; Veerapong, J.; et al. Impact of Perioperative Blood Transfusions on Outcomes After Hyperthermic Intraperitoneal Chemotherapy: A Propensity-Matched Analysis. Ann. Surg. Oncol. 2021, 28, 4499–4507. [Google Scholar] [CrossRef]
- Fisher, O.M.; Alzahrani, N.A.; Kozman, M.A.; Valle, S.J.; Liauw, W.; Morris, D.L. Intraoperative packed red blood cell transfusion (iPRBT) and PCI-normalised iPRBT rates (iPRBT/PCI ratio) negatively affect short- and long-term outcomes of patients undergoing cytoreductive surgery and intraperitoneal chemotherapy—An analysis of 880 patients. Eur. J. Surg. Oncol. 2019, 45, 2412–2423. [Google Scholar] [PubMed]
- Nizri, E.; Kusamura, S.; Fallabrino, G.; Guaglio, M.; Baratti, D.; Deraco, M. Dose-Dependent Effect of Red Blood Cells Transfusion on Perioperative and Long-Term Outcomes in Peritoneal Surface Malignancies Treated with Cytoreduction and HIPEC. Ann. Surg. Oncol. 2018, 25, 3264–3270. [Google Scholar] [CrossRef] [PubMed]
Peritonectomy | Organs |
---|---|
Left parietal | Uterus and ovaries |
Right parietal | Small bowel |
Pelvic cavity | Rectosigmoid colon |
Falciform and umbilical ligaments | Appendix |
Hepatoduodenal ligament | Greater omentum |
Glissonian capsule excision | Stomach |
Epiploic retrocavity | Spleen |
Mesenteric root excision | Liver |
Treitz | Diaphragm |
Diaphragmatic | Others (Gallbladder, Adrenal, Pancreas, Bladder, Ureter, Testicle) |
Median age, years (range) | 58 (26–78) |
Sex, n (%) | |
Female | 1719 (66.7) |
Male | 857 (33.3) |
Median BMI, kg/m2, n (range) | 25 (14–53) |
Previous surgery, n (%) | 1753 (68.1) |
Previous VLS, n (%) | 842 (32.7) |
Previous CHT | 1452 (56.4) |
Histology, n (%) | |
Ovary | 706 (27.4) |
Colon | 577 (22.4) |
PMP | 505 (19.6) |
Mesothelioma | 352 (13.7) |
Appendix | 172 (6.7) |
Stomach | 135 (5.2) |
Other | 129 (5) |
PCI, median (range) | 13 (0–39) |
Median resections, n (range) | 5 (0–14) |
HIPEC technique, n (%) | |
Open | 271 (10.5) |
Closed | 1668 (64.8) |
Semi-open | 637 (24.7) |
Drugs type, n (%) | |
Cisplatin | 287 (11.1) |
Doxorubicin + Cisplatin | 860 (33.4) |
Mytomicin | 400 (15.5) |
Mytomicin + Cisplatin | 744 (28.9) |
Oxaliplatin | 285 (11.1) |
Organs | |
---|---|
Hysteroadnexiectomies | 862 (33.5) |
Greater omentectomy | 1849 (71.8) |
Gastric resection | 211 (8.2) |
Colorectal resection | 1917 (74.4) |
Small bowel resection | 656 (25.5) |
Total colectomy | 134 (5.2) |
Splenectomy | 1023 (39.7) |
Right diaphragm FTR | 1452 (56.4) |
Left diaphragm FTR | 1169 (45.4) |
Pancreatic resection | 44 (1.7) |
Liver metastasectomy | 119 (4.6) |
Appendectomy | 532 (23.7) |
Gallbladder | 1145 (44.6) |
Other (ureter, bladder, testis, adrenal) | 318 (12.3) |
Peritonectomies | |
Glissonian capsule | 729 (28.3) |
Mesenteric root | 211 (8.2) |
Treitz | 266 (10.3) |
Pelvic cavity | 2083 (80.9) |
Epiploic retrocavity | 1316 (51.1) |
Hepatoduodenal ligament | 926 (35.9) |
Falciform and umblical ligaments | 1215 (47.2) |
Right Parietal | 1648 (64) |
Left Parietal | 1574 (61.1) |
Right diaphragmatic S | 1484 (57.6) |
Left diaphragmatic S | 1169 (45.4) |
Surgical Complications | |
---|---|
Bleeding | 218 (22.9%) |
Anastomotic leakage | 70 (7.5%) |
Perforation | 89 (9.5%) |
Abdominal wall eventration | 33 (3.5%) |
Bowel obstruction | 26 (2.8%) |
Ureteral leakage | 20 (2.1%) |
Bilio-pancreatic leakage | 24 (2.5%) |
Abscess | 74 (7.8%) |
Medical Complications | |
Pancreatitis | 28 (2.9%) |
SSI | 59 (6.2%) |
Sepsis | 69 (7.2%) |
Portal thrombosis | 5 (0.5%) |
Pleural effusion | 93 (9.8%) |
Pneumonia | 29 (3%) |
Pulmonary embolism | 33 (3.5%) |
DVT | 5 (0.5%) |
Heart failure | 9 (0.9%) |
Acute Renal Failure | 32 (3.3%) |
Leukopenia | 10 (1.%) |
Neuropathy | 10 (1.%) |
Neurologic syndrome | 10 (1.%) |
TIA | 2 (0.2%) |
DIC | 2 (0.2%) |
MOF | 2 (0.2%) |
Type of Complication | Grade I–II | Grade III | Grade IV | Grade V |
---|---|---|---|---|
Bleeding | 30 (3.4%) | 83 (9.4%) | 97 (11%) | 8 (0.9%) |
Anastomotic leakage | 7 | 20 (2.2%) | 37 (4.2%) | 5 |
Perforation | 13 (1.5%) | 11 (1.2%) | 61 (6.9%) | 3 |
Abdominal wall eventration | 8 | 6 | 16 (1.8%) | - |
Bowel obstruction | 17 (1.9%) | 1 | - | - |
Ureteral leakage | 0 | 17 (1.9%) | 8 | - |
Bilio-pancreatic leakage | 1 | 14 (1.6%) | 3 | 1 |
Abscess | 26 (2.9%) | 39 (4.4%) | 10 (1.1%) | 1 |
Pancreatitis | 16 (1.8%) | 3 | 8 | - |
SSI | 51 (5.8%) | 4 | 3 | - |
Sepsis | 43 (4.9%) | 7 | - | 4 |
Portal thrombosis | 0 | 4 | - | - |
Pleural effusion | 38 (4.3) | 25 (2.8%) | 1 | - |
Pneumonia | 7 | 7 | 3 | 3 |
Pulmonary embolism | 18 (2%) | - | 7 | 11 (1.2%) |
DVT | 2 | - | 2 | - |
Heart failure | 1 | - | - | 4 |
Acute Renal Failure | 9 (0.8%) | 10 (1.1%) | 4 | - |
Leukopenia | 5 | 1 | 5 | - |
Neuropathy | - | 7 | - | - |
Neurologic syndrome | 5 | 1 | - | - |
Transient ischemic attack | 1 | - | 1 | - |
DIC | - | - | - | 1 |
MOF | 1 | - | - | 1 |
Variables | Multivariate Analysis | |
---|---|---|
OR (CI95%) | p | |
Perfusion Type | - | 0.001 |
Semiopen vs. open | 0.978 (0.681–1.404) | 0.905 |
Closed vs. open | 1.455 (1.058–2.001) | 0.021 |
Semiopen vs. open | 0.673 (0.532–0.851) | 0.001 |
Number of resections | 1.179 (1.133–1.227) | <0.0001 |
Body Mass Index | 1.044 (1.022–1.067) | <0.0001 |
Appendectomy yes vs. no | 1.422 (1.126–1.796) | 0.003 |
Colorectal reesctions yes vs. no | 1.526 (1.224–1.902) | <0.0001 |
Variables | Multivariate Analysis | |
---|---|---|
OR (CI95%) | p | |
Number of resections | 1.219 (1.091–1.361) | <0.0001 |
Age | 1.089 (1.047–1.132) | <0.0001 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Carboni, F.; Valle, M.; Vaira, M.; Sammartino, P.; Federici, O.; Robella, M.; Deraco, M.; Framarini, M.; Macrì, A.; Sassaroli, C.; et al. Complications and Mortality Rate of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy: Italian Peritoneal Surface Malignancies Oncoteam Results Analysis. Cancers 2022, 14, 5824. https://doi.org/10.3390/cancers14235824
Carboni F, Valle M, Vaira M, Sammartino P, Federici O, Robella M, Deraco M, Framarini M, Macrì A, Sassaroli C, et al. Complications and Mortality Rate of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy: Italian Peritoneal Surface Malignancies Oncoteam Results Analysis. Cancers. 2022; 14(23):5824. https://doi.org/10.3390/cancers14235824
Chicago/Turabian StyleCarboni, Fabio, Mario Valle, Marco Vaira, Paolo Sammartino, Orietta Federici, Manuela Robella, Marcello Deraco, Massimo Framarini, Antonio Macrì, Cinzia Sassaroli, and et al. 2022. "Complications and Mortality Rate of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy: Italian Peritoneal Surface Malignancies Oncoteam Results Analysis" Cancers 14, no. 23: 5824. https://doi.org/10.3390/cancers14235824
APA StyleCarboni, F., Valle, M., Vaira, M., Sammartino, P., Federici, O., Robella, M., Deraco, M., Framarini, M., Macrì, A., Sassaroli, C., Lippolis, P. V., Di Giorgio, A., Biacchi, D., Martin-Roman, L., Sperduti, I., & Baratti, D. (2022). Complications and Mortality Rate of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy: Italian Peritoneal Surface Malignancies Oncoteam Results Analysis. Cancers, 14(23), 5824. https://doi.org/10.3390/cancers14235824